Ionis Pharmaceuticals, Inc. recently announced its financial results for the fourth quarter and full year ended December 31, 2024. The company exceeded its 2024 financial guidance and provided projections for the full year 2025. Ionis reported total revenue of $227 million for Q4 2024, showcasing substantial results. The revenue included revenue from diverse sources, with key contributors being the launches of WAINUA and TRYNGOLZA in the United States in late January and late December 2024, respectively.
Brett P. Monia, Ph.D., the CEO of Ionis Pharmaceuticals, expressed the company’s strategic direction with the recent launch of TRYNGOLZA as their first independent medicine. He also highlighted upcoming launches scheduled, including donidalorsen for hereditary angioedema and olezarsen for severe hypertriglyceridemia. These launches are pending Phase 3 results later in 2025. Ionis foresees delivering substantial value through its commercial execution and the progression of its pipeline in the upcoming years.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Ionis Pharmaceuticals’s 8K filing here.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
See Also
- Five stocks we like better than Ionis Pharmaceuticals
- Best Stocks Under $5.00
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
- Stock Average Calculator
- Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
- What is a SEC Filing?
- Up Nearly 1000%, Can AppLovin Keep Delivering for Investors?
